Abstract
Objective To systematically evaluate the effect of dexmedetomidine on postoperative cellular immune function in patients with malignant tumor. Methods The Medline, Cochrane Library, EMBASE, PubMed, OVID, Superstar Foreign Languages Database and Chinese Database, CNKI, Chinese Biomedical Literature CD-ROM Database and Wanfang Database were searched, and the publication was not limited by language or time.The randomized controlled trials involving the effect of dexmedetomidine on postoperative cellular immune function in patients with malignant tumor were collected.The evaluation indexes included the levels of whole blood T lymphocyte subsets CD3+ , CD4+ , CD8+ and natural killer cells and ratio of CD4+ /CD8+ .Meta-analysis was conducted using the Cochrane Collaboration′s RevMan 5.2 software. Results Twelve prospective randomized controlled trials involving 692 patients were included in our meta-analysis.Compared with control group, the levels of CD3+ , CD4+ and natural killer cells and ratio of CD4+ /CD8+ were significantly increased at 1 day after operation (P 0.05). Conclusion Dexmedetomidine can improve postoperative cellular immune function in patients with malignant tumors. Key words: Dexmedetomidine; Tumor; Cellular immunity; meta analysis
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
